Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment
Launched by ASAHI KASEI PHARMA CORPORATION · Oct 9, 2012
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Japanese Association for Acute Medicine-defined DIC criteria score \>= 4
- • Written informed consent from patient or guardian
- Exclusion Criteria:
- • Patients showing intracranial, pulmonary, gastrointestinal hemorrhage
- • Patients with a history of cerebrovascular disorders within the past 52 week
- • Patients with a history of hypersensitivity to the ingredients of ART-123 preparations
- • Pregnant women, nursing mothers or possibly pregnant women
About Asahi Kasei Pharma Corporation
Asahi Kasei Pharma Corporation is a leading global pharmaceutical company headquartered in Japan, dedicated to advancing healthcare through innovative research and development. A subsidiary of the Asahi Kasei Group, the company specializes in the discovery, development, and commercialization of novel therapeutics across various therapeutic areas, including cardiovascular, respiratory, and immunology. With a strong commitment to improving patient outcomes, Asahi Kasei Pharma leverages cutting-edge technologies and collaborative partnerships to bring transformative medicines to market, ensuring the highest standards of safety and efficacy in clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oita, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials